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ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYMetformin decreases bone turnover
markers in polycystic ovary
syndrome: a post hoc study
Shilpa Lingaiah, M.B.B.S.,a Laure Morin-Papunen, M.D., Ph.D.,a Juha Risteli, M.D., Ph.D.,b
and Juha S. Tapanainen, M.D., Ph.D.a,c
a Department of Obstetrics and Gynecology, PEDEGOResearch Unit, Medical Research Centre, Oulu University Hospital and
University of Oulu, Oulu; b Department of Clinical Chemistry, OuluUniversity Hospital, Oulu; and c Department ofObstetrics
and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, FinlandObjective: To study the effects of metformin treatment on bone turnover in women with polycystic ovary syndrome (PCOS), as
measured by serum concentrations of bone turnover markers.
Design: Post hoc study of a previously conducted prospective multicenter, placebo-controlled, randomized study.
Setting: University clinic.
Patient(s): The study cohort consisted of 74 non-obese women (body mass index< 27 kg/m2) and 44 obese women (body mass index
R 27 kg/m2) diagnosed with PCOS, with a mean age of 27.6  4.0 (SD) years.
Intervention(s): Randomization to receive metformin or placebo for 3 months.
Main Outcome Measure(s): Serum levels of bone formation marker procollagen type I amino-terminal propeptide (PINP) and bone
resorption marker carboxy-terminal cross-linking telopeptide of type I collagen (CTX) at baseline and after metformin/placebo
treatment.
Result(s): Serum levels of PINP and CTX were similar between the metformin and placebo groups at baseline in the whole study pop-
ulation. Obese women, when compared with non-obese, had lower baseline levels of PINP and CTX. Levels of PINP and CTX were
signiﬁcantly reduced in the whole study population, as well as in both non-obese and obese women after 3 months of metformin
treatment, whereas no signiﬁcant changes were observed in the placebo group.
Conclusion(s): Metformin treatment, when compared with placebo, was associated with reduced bone turnover, as suggested by re-
ductions in markers of bone formation and resorption, leading to slower bone remodeling in premenopausal women with PCOS.
Clinical Trial Registration Number: NCT00994812. (Fertil Steril 2019;-:-–-. 2019 by American Society for Reproductive
Medicine.)
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Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertility-
and-sterility/posts/47362-27473P olycystic ovary syndrome(PCOS) is a common endocrinedisorder in women of reproduc-
tive age, with a prevalence of 6%–
15%, depending on the diagnostic
criteria used (1). Women with PCOS
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alf of the American Society for ReproductiveFurthermore, both androgens and es-
trogens have an independent and
possibly additive association with
peak bone mass attainment and main-
tenance (2). It has been postulated
that hormonal imbalance in women
with PCOS might have a negative effect
on bone formation and bone mineral
density (BMD) (3), but whether it pre-
disposes to osteoporosis in later life re-
mains elusive. Furthermore, few studies
have even reported lower BMD in
women with PCOS compared with their
healthy counterparts (4, 5).
Metformin is one of the widely
used drugs for the treatment of PCOS
and acts by inhibiting hepatic glucose
production and increasing peripheral1
ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYtissue sensitivity to insulin. Long-term treatment with met-
formin has been shown to normalize ovulation, menstrual
cyclicity, and hyperandrogenism (6). Although the exact
mechanism is not fully understood, it is thought that metfor-
min lowers glucose production via activation of the 50 aden-
osine monophosphate-activated protein kinase (AMPK)
pathway (7). Further, AMPK subunits are highly expressed
in bone tissue, osteoblasts, and osteoclasts. Cellular and ani-
mal studies have reported that metformin has a direct osteo-
genic effect and bone loss inhibiting effect (8). Few clinical
studies have evaluated the effects of metformin on bone
metabolism and bone turnover in diabetics, suggesting a
beneﬁcial effect on bone (9). However, there are only limited
data as regards its effect on bone metabolism and measures
of bone turnover in women with PCOS.
Bone, being a metabolically active tissue, undergoes
continuous remodeling, wherein bone formation by osteo-
blasts is coupled to bone resorption by osteoclasts. Bone
formation and resorption can be determined indirectly by
the measurement of serum concentrations of various
biomarkers (i.e., bone matrix components released into the
circulation during bone formation or resorption). The serum
concentrations of bone turnover markers (BTMs) reﬂect
bone remodeling and can be used as markers of the rate
of bone formation and resorption. These markers allow
noninvasive assessment of bone turnover and are sensitive
enough to reﬂect acute changes in it, providing a more
representative view of overall bone loss than that obtained
by measuring the rates of change in BMD at speciﬁc skeletal
sites (10).
Ninety percent of the bone matrix is composed of type I
collagen, which is synthesized as a precursor procollagen,
cleavage of which releases procollagen type I amino-
terminal propeptide (PINP) into the circulation. The
carboxy-terminal cross-linking telopeptide of type I
collagen (CTX) is released from the bone matrix during
resorption and reﬂects the degradation of type I collagen.
Thus, PINP and CTX reﬂect the rates of bone formation
and resorption, respectively (11). The International
Osteoporosis Foundation and the International Federation
of Clinical Chemistry and Laboratory Medicine have
recommended the use of serum PINP and CTX as reference
biochemical markers of bone formation and resorption,
respectively (12).
The present study was a post hoc secondary study
among a subset of patients who have been described in a
previously published prospective multicenter, placebo-
controlled, randomized study on the effects of metformin
on miscarriage, pregnancy and live-birth rates, which
showed that metformin treatment compared with placebo
improved pregnancy and live-birth rates in women with
PCOS (13). The aim of the present study was to investigate
the effects of metformin on bone turnover markers in
women with PCOS. In line with the recommendations of
the International Osteoporosis Foundation and the Interna-
tional Federation of Clinical Chemistry and Laboratory
Medicine, PINP and CTX were used as reference biochem-
ical markers of bone formation and resorption.2MATERIALS AND METHODS
Subjects
The study population consisted of 118 Caucasian women
(mean age 27.6  4.0 [SD] years, mean body mass index
[BMI] 26.5  6.0 kg/m2) diagnosed with PCOS according to
the European Society of Human Reproduction and Embry-
ology/American Society for Reproductive Medicine (ESHRE/
ASRM) consensus deﬁnition (14). The present study was a
post hoc analysis among a subset of subjects who were
selected from a large cohort of subjects in a prospective multi-
center, placebo-controlled randomized study on the effects of
metformin on miscarriage, pregnancy, and live-birth rates
(13). Only the subjects who were examined at Oulu University
Hospital were included in the present study. The primary
study was registered under the clinical trial registration num-
ber NCT00994812 and was approved by the Ethics Committee
of the Northern Ostrobothnia Hospital District (1396/2004)
and the National Supervisory Authority for Welfare and
Health (D1339/05.01.00.06/2009). The primary study was
conducted during 2003–2009, with the ﬁrst patient enrolment
on November 10, 2002.
Women who became pregnant or had a miscarriage
before the study period of 3 months were excluded from the
present study. All women in the present study were examined
and recruited at Oulu University Hospital during 2003–2009.
Informed written consent was obtained from all the subjects.
Women with diabetes, active liver disease (alanine amino-
transferase > 100 IU/L), past or present cardiac failure (New
York Heart Association I–IV), and liver or renal failure
(s-creatinine > 124 mmol/L), women who used alcohol and
hormone preparations, smokers, and pregnant and lactating
women were excluded from the original study. None of the
study subjects were using medications known to affect hor-
monal or metabolic parameters or bone metabolism, and
none had a history of fracture in the preceding 6 months.
The subjects were not allowed to use calcium, vitamin D, di-
etary supplements, herbal therapies, or vitamins during the
study.
Non-obese women (BMI< 27 kg/m2) received metformin
(Diformin; Leiras) at a dose of 500 mg þ 1,000 mg daily, or
placebo; obese women (BMIR 27 kg/m2) received metformin
at a dose of 1,000mg twice daily, or placebo. The limit for BMI
was chosen on the basis of earlier studies that indicated
increased insulin resistance in women with PCOS at a BMI
of 27 kg/m2 (15). The dose of 1,500 mg of metformin for
non-obese women with PCOS and 2,000 mg for obese women
was based on earlier studies (16–18), which showed that
1,500 mg and 2,000 mg of metformin was effective enough
to restore ovulation in most of the non-obese and obese
women with PCOS, respectively, and to improve hyperandro-
genism and insulin sensitivity signiﬁcantly. Furthermore, us-
ing a smaller dose in non-obese women was to minimize
possible side effects, and thereby dropouts.
Clinical, metabolic, and hormonal parameters were
evaluated 1–7 days after spontaneous menstruation in oligo-
menorrheic subjects or at any other convenient time in ame-
norrhoeic subjects. A second evaluation was scheduledVOL.- NO.- /- 2019
TABLE 1
Characteristics of the study population.
Characteristic
Metformin
(n[ 57)
Placebo
(n[ 61) All subjects
PCO þ OA þ HA 21 (36.8) 16 (26.2) 37 (31.4)
PCO þ OA 35 (61.4) 44 (72.1) 79 (66.9)
PCO þ HA 1 (1.8) 1 (1.6) 2 (1.7)
Note. Values are number (percentage). HA¼ hyperandrogenism (serum T level> 2.3 nmol/L
and/or Ferriman-Gallwey hirsutism score of >7); OA ¼ oligoamenorrhea; PCO ¼ polycystic
ovaries on ultrasonography.
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metformin and 61 received placebo for 3 months. Blood sam-
ples were collected in a fasting state at baseline and at
3 months of treatment with metformin/placebo and were
stored at 20 C until the time of analysis.
All study subjects had polycystic ovaries in ultrasonogra-
phy according to the ESHRE/ASRM deﬁnition (14); the
majority of them had oligoamenorrhea (n ¼ 116, 98.3%),
and 39 (33.1%) displayed hyperandrogenism (serum T level
> 2.3 nmol/L, according to the upper limits of our accredited
laboratory in fertile-aged women and/or Ferriman-Gallwey
hirsutism score of >7) (Table 1). Other patient characteristics
at baseline and after 3 months of treatment are shown in
Table 2.Assays
Serum concentrations of PINP, CTX, and 25-hydroxyvitamin
D (25OHD) were determined using the IDS-iSYS Multi-Disci-
pline Analyser (Immunodiagnostics Systems) based on chem-
iluminescence technology, according to the manufacturer's
protocol. In brief, the samples were incubated with speciﬁc
antibodies, followed by the addition of streptavidin-coated
magnetic particles. The magnetic particles were captured,
and trigger reagents were added after further incubation.
The concentration of analytes in the original sample was
directly proportional to the resulting light emitted by the ac-
ridinium label. The reportable ranges of the assays for PINP,
CTX, and 25OHD were 2–230 mg/L, 0.033–6 mg/L, and
5–140 mg/L, respectively. The respective intra- and interassay
coefﬁcients of variation were 4% and 2.2% for PINP, 2.3%
and 1.8% for CTX, and 5.1% and 13% for 25OHD.
Serum concentrations of sex hormone-binding globulin
(SHBG), androstenedione (A), dehydroepiandrosterone sulfate
(DHEAS), and E2 were analyzed, and oral glucose tolerance
tests were carried out after an overnight fast as described
earlier (13). Serum T was analyzed using Agilent triple-
quadrupole 6410 liquid chromatography/mass spectrometry
equipment with an electrospray ionization source operating
in positive-ionmode (Agilent Technologies) as detailed earlier
(13). Multiple reaction monitoring was used to quantify T by
trideuterated T. Intra-assay coefﬁcients of variation of the
method were 5.3%, 1.6%, and 1.2% for T at 0.6, 6.6, and
27.7 nmol/L, respectively. Interassay coefﬁcients of variation
were 5.3%, 4.2%, and 1.0% for the respective concentrations.
The free androgen index (FAI) was calculated using the equa-VOL.- NO.- /- 2019tion: 100  T/SHBG (both as nmol/L). Homeostatic model
assessment of insulin resistance (HOMA-IR) and the whole-
body insulin sensitivity index (i.e., the Matsuda index) were
calculated to quantify the degree of insulin resistance (19, 20).Statistical Methods
Statistical analyses were performed using SPSS 25.0 software
(IBM). Variables with skewed distribution underwent loga-
rithmic transformation. Independent samples t tests were
used for comparisons between the metformin and placebo
groups, and paired-samples t tests were used to evaluate
changes between the measurements at baseline and after
3 months of treatment within the groups. General linear
modeling was used to evaluate the signiﬁcant determinant
of changes in the levels of BTMs. Analysis of correlation be-
tween parameters was performed by using Pearson's correla-
tion coefﬁcient. A value of P< .05 was considered statistically
signiﬁcant.
RESULTS
Baseline Comparisons and Changes after 3Months
of Metformin/Placebo Treatment in Non-obese
and Obese Women
Clinical, hormonal, and metabolic parameters were compara-
ble between metformin and placebo groups at baseline in the
non-obese and obese women (Table 2). There was a small but
statistically signiﬁcant decrease in weight (P¼ .043) and BMI
(P¼ .049) in the obese group after metformin treatment. In
addition, the concentrations of T (P¼ .014) and fasting
glucose (P¼ .004) signiﬁcantly decreased, and the Matsuda
index signiﬁcantly increased (P¼ .046). In the non-obese
group treated with metformin, the concentrations of T
(P¼ .001), the FAI (P< .001), and A (P¼ .001) signiﬁcantly
decreased. No statistically signiﬁcant changes were observed
in any of the clinical, hormonal, and metabolic parameters
during placebo treatment in the non-obese and obese groups.Baseline Comparisons of BTMs and 25OHD
The baseline levels of PINP (P¼ .307), CTX (P¼ .980), and
25OHD (P¼ .281) did not differ between the metformin and
placebo groups in the whole study population. However,
obese women when compared with non-obese women had
signiﬁcantly lower levels of PINP (39.6  15.9 [mean  SD]
mg/L vs. 50.0  21.6 mg/L, P¼ .003) and CTX (0.32 
0.14 mg/L vs. 0.46  0.21 mg/L, P< .001), and similar levels
of 25OHD (22.0  8.0 mg/L vs.19.5  6.4 mg/L, P¼ .076).
Furthermore, in both metformin and placebo groups, obese
women had lower levels of PINP and CTX compared with
non-obese women, though the difference in PINP levels did
not reach statistical signiﬁcance in the metformin group
(Table 3).Changes in BTMs and 25OHD after 3 Months of
Metformin/Placebo Treatment
The levels of PINP and CTX were signiﬁcantly decreased after
3 months of metformin treatment in both non-obese and3
TABLE 2
Clinical, hormonal, and metabolic parameters at baseline and after 3 months of treatment with metformin/placebo in the study population.
Parameter
Non-obese (BMI< 27 kg/m2) (n[ 74) Obese (BMI ‡ 27 kg/m2) (n[ 44)
Metformin (n[ 40) Placebo (n[ 34) Metformin (n[ 17) Placebo (n[ 27)
Baseline 3 mo Baseline 3 mo Baseline 3 mo Baseline 3 mo
Age (y) 27.1 (3.1) 27.9 (4.2) 28.8 (3.8) 27.3 (5.0)
Weight (kg) 61.0 (7.8) 60.4 (7.5) 62.3 (8.7) 62.3 (8.7) 89.7 (11.7) 88.4 (11.8)a 90.0 (14.1) 90.1 (14.0)
BMI (kg/m2) 22.5 (2.2) 22.3 (2.2) 22.7 (2.6) 22.7 (2.5) 33.4 (4.3) 32.9 (4.4)b 33.3 (4.4) 33.3 (4.5)
WHR 0.76 (0.05) 0.76 (0.06) 0.78 (0.06) 0.78 (0.07) 0.83 (0.06) 0.83 (0.05) 0.85 (0.05) 0.84 (0.05)
Hirsutism score 4.8 (3.1) 5.1 (3.3) 4.9 (3.2) 4.6 (2.8) 7.3 (3.7) 7.0 (3.9) 6.7 (4.9) 6.0 (4.7)
E2 (pmol/L) 209.9 (93.8) 204.9 (158.8) 231.2 (98.4) 236.5 (133.4) 204.3 (53.6) 207.2 (98.1) 197.4 (108.4) 200.2 (95.1)
T (nmol/L) 1.6 (0.7) 1.2 (0.6)c 1.7 (0.7) 1.6 (0.6) 1.6 (0.7) 1.3 (0.5)d 1.4 (0.6) 1.5 (1.0)
SHBG (nmol/L) 59.0 (20.2) 70.0 (41.3) 56.6 (18.1) 60.9 (27.0) 43.1 (13.7) 41.9 (16.1) 35.1 (13.7) 36.6 (30.4)
FAI 3.0 (1.9) 2.1 (1.3)c 3.3 (2.2) 3.1 (1.9) 4.2 (2.1) 3.6 (2.1) 4.8 (3.5) 5.0 (3.4)
DHEAS (mmol/L) 5.3 (2.3) 5.6 (2.5) 6.2 (3.3) 6.0 (2.7) 4.9 (2.1) 5.3 (2.2) 5.4 (2.3) 5.3 (1.9)
A (nmol/L) 17.8 (9.5) 14.6 (5.7)e 21.4 (7.7) 20.0 (8.1) 15.7 (5.4) 14.5 (5.7) 17.1 (6.7) 17.9 (8.0)
Fasting glucose
(mmol/L)
5.0 (0.5) 4.9 (0.4) 5.1 (0.4) 5.0 (0.4) 5.3 (0.4) 5.1 (0.3)f 5.3 (0.3) 5.3 (0.3)
Fasting insulin
(mU/L)
5.6 (3.1) 5.8 (2.8) 6.4 (2.8) 7.7 (6.5) 17.2 (17.0) 12.1 (5.9) 14.5 (6.5) 15.0 (7.9)
HOMA-IR 1.3 (0.7) 1.3 (0.6) 1.5 (0.7) 1.8 (1.7) 4.2 (3.8) 2.8 (1.4) 3.4 (1.6) 3.6 (1.9)
Matsuda index 8.3 (3.7) 9.0 (4.7) 7.3 (3.6) 6.6 (3.4) 3.5 (2.3) 4.2 (2.0)g 3.4 (2.1) 3.7 (3.3)
Note. Values are mean (standard deviation). Hirsutism score according to Ferriman-Gallwey criteria. Conversion factor to SI units: insulin, 6.945 (pmol/L). A ¼ androstenedione; BMI ¼ body mass
index; DHEAS ¼ dehydroepiandrosterone sulfate; FAI ¼ free androgen index; HOMA-IR ¼ homeostatic model assessment of insulin resistance; SHBG ¼ sex hormone-binding globulin; WHR ¼
waist-hip ratio.
a–gPaired-samples t test: aP¼ .043; bP¼ .049; cP< .001; dP¼ .014; eP¼ .001; fP¼ .004; gP¼ .046 vs. baseline.
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observed in the placebo group (Fig. 1, Table 3). The average
declines from the baseline values were 25.7% for PINP and
31.1% for CTX in the non-obese women (P< .001 for both)
and 32% for PINP (P< .001) and 24.1% for CTX (P¼ .022) in
the obese women. Concentrations of 25OHD increased in
both non-obese and obese women in the metformin and pla-
cebo groups, although statistically signiﬁcant differences
were observed only in non-obese women in the metformin
group and obese women in the placebo group.Baseline Comparisons of BTMs and 25OHD, and
Changes after 3 Months of Metformin/Placebo
Treatment in Normoandrogenic and
Hyperandrogenic Women
The subjects were further divided into normoandrogenic (NA)
and hyperandrogenic (HA) (serum T level> 2.3 nmol/L and/or
Ferriman-Gallwey hirsutism score of >7). The baseline con-
centrations of PINP, CTX, and 25OHD were comparable be-
tween NA and HA women in the metformin and placebo
groups. The levels of PINP and CTX were signiﬁcantly
decreased after 3 months of metformin treatment in both
NA (P< .001 for PINP and CTX) and HA women (P¼ .002
for PINP, P¼ .001 for CTX), whereas no signiﬁcant differences
were observed in the placebo group (Supplemental Table 1,
available online). The average declines from the baseline
values were 30% for PINP and 31% for CTX in NA women,
and 22.8% for PINP and 27% for CTX in HA women. The
levels of 25OHD were increased in NA women in both metfor-
min (P¼ .013) and placebo groups (P¼ .006).4Correlation Analyses and General LinearModeling
Changes in PINP and CTX levels did not show any statistically
signiﬁcant correlations when compared with changes in the
levels of E2, T, SHBG, the FAI, A, DHEAS, fasting glucose,
fasting insulin, HOMA-IR, or Matsuda index during metfor-
min treatment. In general linear modeling, only metformin
treatment, not BMI group or androgenic status, showed a sta-
tistically signiﬁcant interaction with the changes in the levels
of PINP (P< .001) and CTX (P¼ .001). As regards the changes
in 25OHD levels, metformin treatment (P¼ .772) and BMI
(P¼ .442) did not show any signiﬁcant interactions.DISCUSSION
The present study showed that serum levels of the bone for-
mation marker PINP and the bone resorption marker CTX
signiﬁcantly decreased during treatment with metformin in
women with PCOS compared with those treated with placebo.
During 3 months of metformin treatment, the average de-
clines of PINP and CTX levels from baseline values were
27.4% and 30%, respectively, in the whole population.
Furthermore, the signiﬁcant decreases in the levels of PINP
and CTX were observed in both non-obese and obese women
with PCOS in the metformin group.
Bone turnover depends on bone formation and resorption
through cross-talk between osteoblasts and osteoclasts.
Reduced levels of markers of bone formation and resorption
are associated with low bone turnover and a slower rate
of bone loss. Studies have shown that low bone turnover
could slow bone loss and give rise to a bone density exceeding
that expected for age. Conversely, increased bone turnoverVOL.- NO.- /- 2019
TABLE 3
Bone turnover markers and 25OHD at baseline and after 3 months of treatment with metformin/placebo in the study population.
Treatment
PINP (mg/L)
at baseline
PINP (mg/L)
after 3 mo
P
valuea
CTX (mg/L)
at baseline
CTX (mg/L)
after 3 mo
P
valuea
25OHD (mg/L)
at baseline
25OHD (mg/L)
after 3 mo
P
valuea
Metformin
All women 44.2 (19.1) 32.1 (13.0) < .001 0.40 (0.20) 0.28 (0.15) < .001 20.3 (7.3) 23.2 (8.7) .003
BMI < 27 kg/m2 47.0 (19.4)b 34.9 (13.0) < .001 0.45 (0.20)c 0.31 (0.16) < .001 21.6 (7.9) 24.3 (8.8) .017
BMIR 27 kg/m2 37.5 (16.9)b 25.5 (10.8) < .001 0.29 (0.14)c 0.22 (0.10) .022 17.4 (4.9) 20.7 (8.1) .106
Placebo
All women 48.0 (21.3) 47.1 (21.4) .576 0.40 (0.20) 0.38 (0.20) .147 21.8 (7.7) 24.8 (9.9) .007
BMI < 27 kg/m2 53.6 (23.7)c 53.8 (24.6) .907 0.47 (0.22)e 0.45 (0.22) .433 22.6 (8.2) 24.8 (11.1) .101
BMIR 27 kg/m2 41.0 (15.4)d 38.7 (12.5) .361 0.33 (0.14)e 0.30 (0.15) .188 20.8 (7.0) 24.8 (8.3) .036
Note. Values are mean (standard deviation). 25OHD¼ 25-hydroxyvitamin D; BMI¼ body mass index; CTX¼ carboxy-terminal cross-linking telopeptide of type I collagen; PINP¼ procollagen type I
amino-terminal propeptide.
aP values according to paired-samples t test.
b–eP values according to independent samples t tests for baseline comparisons in the same treatment group: bP¼ .083; cP¼ .015; dP¼ .001; eP¼ .004.
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deterioration in bone quality (8, 21). Bone turnover markers
reﬂect whole-body bone turnover, underlying changes in
bone mass and bone histomorphometric parameters, and are
thus predictive of total-body bone loss. Furthermore, there
is a moderate association between baseline levels of BTMs
and subsequent changes in BMD (22).
Cellular studies have shown that metformin is a potent
stimulator of AMPK activation in osteoblasts, resulting inFIGURE 1
Concentrations of bone turnover markers at baseline and after 3 mont
syndrome. The bars represent means and the error bars standard dev
collagen; PINP ¼ procollagen type I amino-terminal propeptide. *P¼.022;
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VOL.- NO.- /- 2019their differentiation and mineralization, and stimulates
type 1 collagen production in osteoblast-like cell lines, sug-
gesting a direct osteogenic effect (23–25), whereas few
studies have not shown such an effect (26, 27). It has been
reported that treatment with metformin prevents bone loss
in ovariectomized rats, suggesting protective effects of
metformin against bone loss (28, 29). In contrast, one study
showed that metformin has no effect on bone mass in
rodents (30).hs of metformin/placebo treatment in women with polycystic ovary
iations. CTX ¼ carboxy-terminal cross-linking telopeptide of type I
**P<.001.
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PCOS are still lacking, even though metformin is widely
used in the treatment of the condition. In clinical studies,
the effect of metformin on bone has been investigated
mainly in diabetics. It has been reported that metformin re-
duces fracture risk in patients with type 2 diabetes mellitus
(T2DM) (9), whereas one study found no association be-
tween metformin and fracture incidents (31). Furthermore,
it has also been reported that metformin decreases the
markers of bone formation and resorption and bone remod-
eling in T2DM (32).
In the present study, the baseline levels of BTMs in obese
women with PCOS were already decreased when compared
with non-obese women. Similar results have been observed
in healthy premenopausal women with higher BMI (33). It
has been postulated that higher BMI may be associated with
increased secretion of various hormones from adipocytes
(including estrogen), inﬂuencing osteoblast and osteoclast
activity (34). In the present study, however, the E2 levels in
obese women with PCOS were not increased when compared
with those of non-obese women. Furthermore, the concentra-
tions of E2 remained unchanged throughout the treatment
period in both groups, suggesting that the decrease in BTMs
may not be related to E2 effect.
Androgens have been shown to inﬂuence bone meta-
bolism directly through their action on osteoblasts by pro-
moting bone formation, and also indirectly by inhibition of
bone resorption (2). Furthermore, SHBG plays a crucial role
in bone metabolism and remodeling because it binds to T
and 17b-E2, thereby regulating their bioavailability and ac-
cess to target cells (35), and may play a role in the determina-
tion of bone mass in premenopausal women. In the present
study, the concentrations of T decreased in both non-obese
and obese women with PCOS, and FAI decreased in non-
obese women treated with metformin, which might be associ-
ated with decreased levels of BTMs. However, the changes in
T, SHBG, and FAI levels during metformin treatment did not
correlate with the changes in the levels of BTMs. Furthermore,
the decrease in the levels of BTMs was not dependent on the
androgen status of the women, because both NA and HA
women with PCOS showed similar declines.
Increased mechanical loading secondary to increased
body weight stimulates bone formation through stimulation
of osteoblast activity (36). Body weight, covering fat mass
and lean mass, has an impact on both bone turnover and
bone density. In the present study, there was a decrease in
BTMs in both obese and non-obese subjects in the metformin
group, suggesting that metformin, not body weight, was the
inﬂuencing factor in bone turnover. It is possible that the ef-
fect of metformin on BTMs is mediated via other mechanisms
at the cellular level, which has to be investigated in future
studies.
The important prohormone 25OHD inﬂuences BMD by
regulating calcium metabolism, but 25OHD per se may not
have any signiﬁcant inﬂuence on BTMs (37). Even though
25OHD levels showed an increasing trend in non-obese and
obese subjects in both treatment groups, signiﬁcant increases6were observed only in the non-obese subjects treated with
metformin and obese subjects treated with placebo. It must
be noted that the seasonal variation of 25OHD levels was
not taken into account in the present study, which could be
one explanation for the differences observed between the
two treatment groups. Furthermore, studies on the effect of
metformin on 25OHD levels are sparse, with conﬂicting re-
sults. It has been reported that treatment with metformin in
T2DM has no effect on 25OHD levels (38, 39), whereas one
study revealed that metformin improves 25OHD levels (40).
According to the Endocrine Society Clinical Practice
Guideline (41), almost half (51%) of our study population
was vitamin D deﬁcient [25(OH)D below 20 mg/L], and 34%
had vitamin D insufﬁciency [25(OH)D of 21–29 mg/L]. This
is in line with studies reporting low levels of 25OHD in women
with PCOS (42). Bone turnover markers decreased signiﬁ-
cantly in the metformin group compared with the placebo
group in women with both deﬁcient and insufﬁcient vitamin
D levels (Supplemental Table 2), suggesting that the decrease
in BTMs was not dependent on vitamin D levels in our study
population.
There are several strengths as well as limitations in our
study. A potential limitation may be the selection of the study
subjects: this is a post hoc analysis of a previously conducted
study. However, the subjects who participated in the present
study did not differ from the subjects of the primary study
as regards PCOS phenotypes or anthropometric, hormonal,
and metabolic parameters (data not shown). The duration of
the treatment was 3 months, which may be a limiting factor.
There is an interplay between resorption and formation
locally in bone, meaning that when resorption increases for-
mation increases, and vice versa. However, resorption is a
faster process (2 to 3 weeks) when compared with formation
(3 months) (43, 44). Thus, the present study period of
3 months should have been sufﬁcient to depict changes in
bone formation and resorption reﬂected by BTMs. The
factors leading to biological variability in BTMs were
minimized, because all blood samples were collected in a
fasting state. This is particularly important as regards CTX
levels, because they decrease by approximately 20% after
food intake (11). Because none of the study subjects had
any active liver disease or history of renal failure, the
effects of clearance of PINP and CTX from the circulation
by hepatic endothelium and the kidneys were controlled.
The timing of samples was not scheduled according to the
season, but earlier studies have shown that there is no
signiﬁcant seasonal variation in the levels of BTMs (45).
The samples were taken during the follicular phase in
oligomenorrheic women and at any time in amenorrhoeic
women. Previous studies have shown that variations in the
levels of BTMs over the menstrual cycle are so small that
the effect of the menstrual cycle can be considered to be
insigniﬁcant (10, 11). The effect of oligo-amenorrhea
compared with regular menstrual cycles on BTMs could not
be analyzed in the present study, because there were few
women with regular cycles. Even though the study period of
3 months was sufﬁcient to show the changes in the levelsVOL.- NO.- /- 2019
Fertility and Sterility®of BTMs, the effect of treatment with metformin should be
assessed during a longer study period to account for its effect
on various hormonal and metabolic parameters.
In conclusion, metformin treatment of premenopausal
women with PCOS for 3 months was associated with reduced
bone turnover, as suggested by reductions in markers of
bone formation and resorption, leading to slower bone
remodeling preventing bone loss. However, long-term
intervention studies with BMD measurements and fracture
assessment are necessary to demonstrate the effects of
metformin on bone turnover and remodeling in PCOS
conclusively.
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